Clinical Study on Qiangli Pipa Syrup Combined with Budesonide Formoterol Inhalation in Treating Cough Variant Asthma
Objective:To observe the clinical effect of Qiangli Pipa Syrup combined with Budesonide Formoterol Inhalation in the treatment of cough variant asthma(CVA).Methods:A total of 96 patients with CVA admitted to Putuo District People's Hospital of Zhoushan from January 2022 to January 2024 were selected and randomly divided into the western medicine group and the combination group,with 48 patients in each group.The western medicine group was treated with Budesonide Formoterol Inhalation,and the combination group was treated with oral administration of Qiangli Pipa Syrup based on the treatment of the western medicine group.Both groups were treated for four consecutive weeks.Clinical effects were evaluated in the two groups.The changes in the cough symptom scores,lung function[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),and peak expiratory flow percentage(PEFpred%)],and the levels of inflammatory indicators[eosinophil percentage(EOS%)and immunoglobulin E(IgE)]were compared between the two groups before and after treatment.The incidence of adverse reactions was counted.Results:The total effective rate in the combination group was 97.92%(47/48),which was higher than that in the western medicine group at 85.42%(41/48)(P＜0.05).The disappearance time of cough and wheezing symptoms in the combination group was shorter than that in the western medicine group(P＜0.05).After treatment,the daytime and nighttime cough symptom scores in the two groups were declined when compared with those before treatment(P＜0.05),and the daytime and nighttime cough symptom scores in the combination group were lower than those in the western medicine group(P＜0.05).After treatment,the levels of FEV1,FVC,and PEFpred%in the two groups were increased when compared with those before treatment(P＜0.05),and the levels of FEV1,FVC,and PEFpred%in the combination group were higher than those in the western medicine group(P＜0.05).After treatment,the levels of EOS and IgE in the two groups were decreased when compared with those before treatment(P＜0.05),and the EOS and IgE levels in the combination group were lower than those in the western medicine group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:The combination of Qiangli Pipa Syrup and Budesonide Formoterol Inhalation is effective in treating CVA,which can improve patients'lung function and alleviate respiratory inflammation,with few adverse reactions and high safety.
万方数据
维普
